Download PDF
Horm Metab Res
DOI: 10.1055/a-2231-9192
Original Article: Endocrine Care

Meta-Analysis of the Efficacy and Safety Evaluation of Vandetanib in the Treatment of Medullary Thyroid Cancer

Tong-cheng Xian
1   Department of Thyroid and Breast Surgery, the Nanchong City Central Hospital Affiliated to North Sichuan Medical College, Nanchong, China
,
Min-ye Yang
1   Department of Thyroid and Breast Surgery, the Nanchong City Central Hospital Affiliated to North Sichuan Medical College, Nanchong, China
,
Xue-lin Zhang
1   Department of Thyroid and Breast Surgery, the Nanchong City Central Hospital Affiliated to North Sichuan Medical College, Nanchong, China
,
Jie Wang
1   Department of Thyroid and Breast Surgery, the Nanchong City Central Hospital Affiliated to North Sichuan Medical College, Nanchong, China
,
Yi Luo
1   Department of Thyroid and Breast Surgery, the Nanchong City Central Hospital Affiliated to North Sichuan Medical College, Nanchong, China
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

The aim of the work was to systematically evaluate the efficacy and safety of Vandetanib in the treatment of advanced medullary thyroid carcinoma (MTC). MeSH entries to search for randomized controlled trials and clinical research literature on the application of Vandetanib in the treatment of medullary thyroid cancer from PubMed, Chinese national knowledge infrastructure (CNKI), and Web of Science databases since their establishment until March 2023 were used. In terms of efficacy, the analysis results showed that Vandetanib had a significantly higher objective response rate compared to the control group using placebo (OR=2.13, 95% CI: 1.38, 3.29). In terms of side effects, Vandetanib significantly increases the incidence of hypertension, rash, and diarrhea, and has statistical significance (p+<+0.05). Vandetanib has a better therapeutic effect on MTC, but it also increases the incidence of hypertension, rash, and diarrhea. Attention should be paid to the relief of side effects when using it.

Key words

medullary thyroid carcinoma - Vandetanib - objective response rate - side effects - meta-analysis

Supplementary Material



Publication History

Received: 27 October 2023

Accepted after revision: 06 December 2023

Article published online:
26 January 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Kim M, Kim BH. Current guidelines for management of medullary thyroid Carcinoma. Endocrinol Metab (Seoul) 2021; 36: 514-524
    CrossrefPubMedGoogle Scholar
  • 2 Baloch ZW, Asa SL, Barletta JA. et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol 2022; 33: 27-63
    CrossrefPubMedGoogle Scholar
  • 3 Jayasinghe R, Basnayake O, Jayarajah U. et al. Management of medullary carcinoma of the thyroid: a review. J Int Med Res 2022; 50: 3000605221110698
    CrossrefPubMedGoogle Scholar
  • 4 Ceolin L, Duval M, Benini AF. et al. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives. Endocr Relat Cancer 2019; 26: R499-R518
    CrossrefPubMedGoogle Scholar
  • 5 Leimbach RD, Hoang TD, Shakir MKM. Diagnostic challenges of medullary thyroid carcinoma. Oncology 2021; 99: 422-432
    CrossrefPubMedGoogle Scholar
  • 6 Filetti S, Durante C, Hartl D. et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 2019; 30: 1856-1883
    CrossrefPubMedGoogle Scholar
  • 7 De Luca A, D’Alessio A, Maiello MR. et al. Vandetanib as a potential treatment for breast cancer. Expert Opin Investig Drugs 2014; 23: 1295-1303
    CrossrefPubMedGoogle Scholar
  • 8 Morabito A, Piccirillo MC, Costanzo R. et al. Vandetanib: an overview of its clinical development in NSCLC and other tumors. Drugs Today (Barc). 2010. 46. 683-698
    Google Scholar
  • 9 Wells SA, Robinson BG, Gagel RF. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30: 134-141
    CrossrefPubMedGoogle Scholar
  • 10 Wang SX, Zhang XW, Wang XX. et al. [Efficacy and safety of vandetanib on advanced medullary thyroid carcinoma: single center result from a phase III study]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2019; 54: 439-444
    PubMedGoogle Scholar
  • 11 Uchino K, Komoda M, Tomomatsu J. et al. Safety and tolerability of vandetanib in Japanese patients with medullary thyroid cancer: a phase I/Ii open-label study. Endocr Pract 2017; 23: 149-156
    CrossrefPubMedGoogle Scholar
  • 12 Robinson BG, Paz-Ares L, Krebs A. et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95: 2664-2671
    CrossrefPubMedGoogle Scholar
  • 13 Wells SA, Gosnell JE, Gagel RF. et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010; 28: 767-772
    CrossrefPubMedGoogle Scholar
  • 14 Zhang L, Li S, Zhang Y. et al. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. Clin Ther 2011; 33: 315-327
    CrossrefPubMedGoogle Scholar
  • 15 Hu MI, Elisei R, Dedecjus M. et al. Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. Endocr Relat Cancer 2019; 26: 241-250
    CrossrefPubMedGoogle Scholar
  • 16 Fallahi P, Ferrari SM, Galdiero MR. et al. Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Semin Cancer Biol 2022; 79: 180-196
    CrossrefPubMedGoogle Scholar
  • 17 Tsang VH, Robinson BG, Learoyd DL. The safety of vandetanib for the treatment of thyroid cancer. Expert Opin Drug Saf 2016; 15: 1107-1113
    CrossrefPubMedGoogle Scholar
  • 18 Leboulleux S, Bastholt L, Krause T. et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012; 13: 897-905
    CrossrefPubMedGoogle Scholar
  • 19 Chougnet CN, Borget I, Leboulleux S. et al. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort. Thyroid 2015; 25: 386-391
    CrossrefPubMedGoogle Scholar
  • 20 Weber MA, Schiffrin EL, White WB. et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32: 3-15
    CrossrefPubMedGoogle Scholar